The basic immunology of asthma

In many asthmatics, chronic airway inflammation is driven by IL-4-, IL-5-, and IL-13-producing Th2 cells or ILC2s. Type 2 cytokines promote hallmark features of the disease such as eosinophilia, mucus hypersecretion, bronchial hyperresponsiveness (BHR), IgE production, and susceptibility to exacerba...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cell 2021-03, Vol.184 (6), p.1469-1485
Hauptverfasser: Hammad, Hamida, Lambrecht, Bart N.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1485
container_issue 6
container_start_page 1469
container_title Cell
container_volume 184
creator Hammad, Hamida
Lambrecht, Bart N.
description In many asthmatics, chronic airway inflammation is driven by IL-4-, IL-5-, and IL-13-producing Th2 cells or ILC2s. Type 2 cytokines promote hallmark features of the disease such as eosinophilia, mucus hypersecretion, bronchial hyperresponsiveness (BHR), IgE production, and susceptibility to exacerbations. However, only half the asthmatics have this “type 2-high” signature, and “type 2-low” asthma is more associated with obesity, presence of neutrophils, and unresponsiveness to corticosteroids, the mainstay asthma therapy. Here, we review the underlying immunological basis of various asthma endotypes by discussing results obtained from animal studies as well as results generated in clinical studies targeting specific immune pathways. Hammad and Lambrecht review the immunological basis of asthma endotypes by discussing results from animal studies that have unraveled molecular pathways and clinical studies targeting specific immune pathways using molecule-specific biologics.
doi_str_mv 10.1016/j.cell.2021.02.016
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_33711259</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0092867421001665</els_id><sourcerecordid>2501258349</sourcerecordid><originalsourceid>FETCH-LOGICAL-c449t-311b0060f48b969e03b11656f2881118e01c6888ce7b8d588dc56a4f1c3915653</originalsourceid><addsrcrecordid>eNqNkE1Lw0AQhhdRbK3-AQ-lR0ESZ3azmw14keAXFLzU85JsNnZLk63ZROm_d0trj-JphuF5hpmXkGuEGAHF3SrWZr2OKVCMgcZhdELGCFkaJZjSUzIGyGgkRZqMyIX3KwCQnPNzMmIsRaQ8G5PpYmlmZeGtntmmGVq3dh_bmatnhe-XTXFJzupi7c3VoU7I-9PjIn-J5m_Pr_nDPNJJkvURQywBBNSJLDORGWAlouCiplIiojSAWkgptUlLWXEpK81FkdSoWYZccDYhN_u9m859Dsb3qrF-913RGjd4RTmEeyVLsoDSPao7531narXpbFN0W4WgdrmoldqZapeLAqrCKEjTw_6hbEx1VH6DCMDtHvg2pau9tqbV5oiF5AQDxtMkdMgCLf9P57Yveuva3A1tH9T7vWpCnF_WdOqgV7YzuleVs3898gPbDpDn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2501258349</pqid></control><display><type>article</type><title>The basic immunology of asthma</title><source>Cell Press Free Archives</source><source>Access via ScienceDirect (Elsevier)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Hammad, Hamida ; Lambrecht, Bart N.</creator><creatorcontrib>Hammad, Hamida ; Lambrecht, Bart N.</creatorcontrib><description>In many asthmatics, chronic airway inflammation is driven by IL-4-, IL-5-, and IL-13-producing Th2 cells or ILC2s. Type 2 cytokines promote hallmark features of the disease such as eosinophilia, mucus hypersecretion, bronchial hyperresponsiveness (BHR), IgE production, and susceptibility to exacerbations. However, only half the asthmatics have this “type 2-high” signature, and “type 2-low” asthma is more associated with obesity, presence of neutrophils, and unresponsiveness to corticosteroids, the mainstay asthma therapy. Here, we review the underlying immunological basis of various asthma endotypes by discussing results obtained from animal studies as well as results generated in clinical studies targeting specific immune pathways. Hammad and Lambrecht review the immunological basis of asthma endotypes by discussing results from animal studies that have unraveled molecular pathways and clinical studies targeting specific immune pathways using molecule-specific biologics.</description><identifier>ISSN: 0092-8674</identifier><identifier>EISSN: 1097-4172</identifier><identifier>DOI: 10.1016/j.cell.2021.02.016</identifier><identifier>PMID: 33711259</identifier><language>eng</language><publisher>CAMBRIDGE: Elsevier Inc</publisher><subject>asthma ; Biochemistry &amp; Molecular Biology ; biologics ; Cell Biology ; endotypes ; immune cells ; Life Sciences &amp; Biomedicine ; lung ; Science &amp; Technology</subject><ispartof>Cell, 2021-03, Vol.184 (6), p.1469-1485</ispartof><rights>2021 Elsevier Inc.</rights><rights>Copyright © 2021 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>451</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000630357400013</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c449t-311b0060f48b969e03b11656f2881118e01c6888ce7b8d588dc56a4f1c3915653</citedby><cites>FETCH-LOGICAL-c449t-311b0060f48b969e03b11656f2881118e01c6888ce7b8d588dc56a4f1c3915653</cites><orcidid>0000-0003-4376-6834</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cell.2021.02.016$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27928,27929,45999</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33711259$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hammad, Hamida</creatorcontrib><creatorcontrib>Lambrecht, Bart N.</creatorcontrib><title>The basic immunology of asthma</title><title>Cell</title><addtitle>CELL</addtitle><addtitle>Cell</addtitle><description>In many asthmatics, chronic airway inflammation is driven by IL-4-, IL-5-, and IL-13-producing Th2 cells or ILC2s. Type 2 cytokines promote hallmark features of the disease such as eosinophilia, mucus hypersecretion, bronchial hyperresponsiveness (BHR), IgE production, and susceptibility to exacerbations. However, only half the asthmatics have this “type 2-high” signature, and “type 2-low” asthma is more associated with obesity, presence of neutrophils, and unresponsiveness to corticosteroids, the mainstay asthma therapy. Here, we review the underlying immunological basis of various asthma endotypes by discussing results obtained from animal studies as well as results generated in clinical studies targeting specific immune pathways. Hammad and Lambrecht review the immunological basis of asthma endotypes by discussing results from animal studies that have unraveled molecular pathways and clinical studies targeting specific immune pathways using molecule-specific biologics.</description><subject>asthma</subject><subject>Biochemistry &amp; Molecular Biology</subject><subject>biologics</subject><subject>Cell Biology</subject><subject>endotypes</subject><subject>immune cells</subject><subject>Life Sciences &amp; Biomedicine</subject><subject>lung</subject><subject>Science &amp; Technology</subject><issn>0092-8674</issn><issn>1097-4172</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><recordid>eNqNkE1Lw0AQhhdRbK3-AQ-lR0ESZ3azmw14keAXFLzU85JsNnZLk63ZROm_d0trj-JphuF5hpmXkGuEGAHF3SrWZr2OKVCMgcZhdELGCFkaJZjSUzIGyGgkRZqMyIX3KwCQnPNzMmIsRaQ8G5PpYmlmZeGtntmmGVq3dh_bmatnhe-XTXFJzupi7c3VoU7I-9PjIn-J5m_Pr_nDPNJJkvURQywBBNSJLDORGWAlouCiplIiojSAWkgptUlLWXEpK81FkdSoWYZccDYhN_u9m859Dsb3qrF-913RGjd4RTmEeyVLsoDSPao7531narXpbFN0W4WgdrmoldqZapeLAqrCKEjTw_6hbEx1VH6DCMDtHvg2pau9tqbV5oiF5AQDxtMkdMgCLf9P57Yveuva3A1tH9T7vWpCnF_WdOqgV7YzuleVs3898gPbDpDn</recordid><startdate>20210318</startdate><enddate>20210318</enddate><creator>Hammad, Hamida</creator><creator>Lambrecht, Bart N.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4376-6834</orcidid></search><sort><creationdate>20210318</creationdate><title>The basic immunology of asthma</title><author>Hammad, Hamida ; Lambrecht, Bart N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c449t-311b0060f48b969e03b11656f2881118e01c6888ce7b8d588dc56a4f1c3915653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>asthma</topic><topic>Biochemistry &amp; Molecular Biology</topic><topic>biologics</topic><topic>Cell Biology</topic><topic>endotypes</topic><topic>immune cells</topic><topic>Life Sciences &amp; Biomedicine</topic><topic>lung</topic><topic>Science &amp; Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hammad, Hamida</creatorcontrib><creatorcontrib>Lambrecht, Bart N.</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cell</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hammad, Hamida</au><au>Lambrecht, Bart N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The basic immunology of asthma</atitle><jtitle>Cell</jtitle><stitle>CELL</stitle><addtitle>Cell</addtitle><date>2021-03-18</date><risdate>2021</risdate><volume>184</volume><issue>6</issue><spage>1469</spage><epage>1485</epage><pages>1469-1485</pages><issn>0092-8674</issn><eissn>1097-4172</eissn><abstract>In many asthmatics, chronic airway inflammation is driven by IL-4-, IL-5-, and IL-13-producing Th2 cells or ILC2s. Type 2 cytokines promote hallmark features of the disease such as eosinophilia, mucus hypersecretion, bronchial hyperresponsiveness (BHR), IgE production, and susceptibility to exacerbations. However, only half the asthmatics have this “type 2-high” signature, and “type 2-low” asthma is more associated with obesity, presence of neutrophils, and unresponsiveness to corticosteroids, the mainstay asthma therapy. Here, we review the underlying immunological basis of various asthma endotypes by discussing results obtained from animal studies as well as results generated in clinical studies targeting specific immune pathways. Hammad and Lambrecht review the immunological basis of asthma endotypes by discussing results from animal studies that have unraveled molecular pathways and clinical studies targeting specific immune pathways using molecule-specific biologics.</abstract><cop>CAMBRIDGE</cop><pub>Elsevier Inc</pub><pmid>33711259</pmid><doi>10.1016/j.cell.2021.02.016</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0003-4376-6834</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0092-8674
ispartof Cell, 2021-03, Vol.184 (6), p.1469-1485
issn 0092-8674
1097-4172
language eng
recordid cdi_pubmed_primary_33711259
source Cell Press Free Archives; Access via ScienceDirect (Elsevier); EZB-FREE-00999 freely available EZB journals
subjects asthma
Biochemistry & Molecular Biology
biologics
Cell Biology
endotypes
immune cells
Life Sciences & Biomedicine
lung
Science & Technology
title The basic immunology of asthma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T10%3A19%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20basic%20immunology%20of%20asthma&rft.jtitle=Cell&rft.au=Hammad,%20Hamida&rft.date=2021-03-18&rft.volume=184&rft.issue=6&rft.spage=1469&rft.epage=1485&rft.pages=1469-1485&rft.issn=0092-8674&rft.eissn=1097-4172&rft_id=info:doi/10.1016/j.cell.2021.02.016&rft_dat=%3Cproquest_pubme%3E2501258349%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2501258349&rft_id=info:pmid/33711259&rft_els_id=S0092867421001665&rfr_iscdi=true